معرفی
Dimitrios (Dimitris) Anastasiou is a Senior Group Leader at The Francis Crick Institute in London, UK, specializing in cancer metabolism research. Previously, he served as a Group Leader at the Medical Research Council National Institute for Medical Research (NIMR) starting in 2012 before transitioning to the Crick Institute in 2015. His research career includes postdoctoral work and an Instructor position at Beth Israel Deaconess Medical Center and the Department of Systems Biology, Harvard Medical School under Lewis Cantley, where he focused on metabolic reprogramming in cancer.
- University College London, UK - BSc Molecular Biology (2001)
- University of Basel, Basel, Switzerland - PhD in Biochemistry (2006)
Anastasiou's research centers on understanding how cancer cells generate energy and utilize nutrients differently from normal cells. His laboratory conducts detailed analyses of metabolic pathways in cancer, investigating how tumor cells rewire their metabolism to support rapid growth and evade the body's defenses. His work spans biochemistry, proteomics, computational systems biology, human physiology, and tumor biology, with particular emphasis on identifying metabolic vulnerabilities that could be targeted for cancer therapy. His innovative approaches include developing chemical 'sensors' to monitor metabolic changes in cancer cells over time as tumors develop.
Analysis of his recent publications reveals a consistent focus on metabolic regulation in cancer, particularly regarding glycolysis, hypoxia response, amino acid metabolism, and nucleotide biosynthesis. His work frequently examines enzyme regulation (particularly PKM2), metabolic adaptation to environmental stressors, and the intersection between metabolism and signaling pathways. A notable trend is his exploration of how metabolic enzymes function beyond their traditional roles, influencing cellular signaling and gene expression in cancer contexts.
Anastasiou has made significant contributions to understanding metabolic reprogramming in cancer, particularly regarding pyruvate kinase M2 regulation, hypoxia responses, and nutrient utilization in tumor microenvironments. His work bridges basic biochemical mechanisms with potential therapeutic applications, focusing on identifying metabolic vulnerabilities in cancer cells that could be exploited for treatment.
As a Senior Group Leader at the Crick Institute, Anastasiou leads a research group investigating how metabolism contributes to disease, particularly cancer. His laboratory utilizes a range of techniques including metabolomics, bioinformatics, structural biology, and high-throughput screening to study metabolic pathways. The group's work aims to identify fundamental differences between metabolic pathways in tumors and healthy tissue to discover new therapeutic targets against cancer.
